Auranofin in the treatment of steroid dependent asthma: a double blind study.

BACKGROUND: Long term administration of oral corticosteroids in patients with asthma may be associated with serious side effects. Non-steroidal anti-inflammatory drugs, including gold salts, have been shown to reduce the need for systemic corticosteroid treatment in uncontrolled studies. The effect of oral gold (auranofin) on asthma symptoms, lung function, and the need for oral prednisone treatment was investigated. METHODS: A 26 week randomised, double blind, placebo controlled, parallel group trial of auranofin was performed in 32 patients with moderately severe chronic asthma who required an oral corticosteroid dose of at least 5 mg prednisone a day (or equivalent) or 2.5 mg/day prednisone plus more than 800 micrograms/day inhaled corticosteroids. Auranofin was given orally in a dose of 3 mg twice daily. Asthma symptoms, lung function, and adverse effects were assessed at regular intervals. After 12 weeks of treatment prednisone dosage was tapered down by 2.5 mg every two weeks if the patient was clinically stable. Asthma exacerbations were treated with short courses of high doses of oral steroids. RESULTS: Twenty eight of the 32 patients, 13 in the placebo group and 15 in the auranofin group, completed the study. The total corticosteroid reduction achieved after 26 weeks of treatment was significantly greater (4 mg) in the auranofin group than in the placebo group (0.3 mg). The number of exacerbations requiring an increase of steroids was greater in the placebo group (2.1) than in the active group (0.9). A significant increase in FEV1 of 6.4% predicted occurred in the auranofin group during the study and there was a reduction of asthma symptoms such as wheezing and cough. There was no difference between the groups in peak flow measurements or in the number of asthma attacks. The incidence of side effects of auranofin was low, but exacerbations of constitutional eczema were noticeable. CONCLUSION: Auranofin provides an effective adjunct to treatment for steroid dependent asthma, leading to a reduction of oral steroid dose.

[1]  C. Reed.  Aerosol glucocorticoid treatment of asthma. Adults. , 1990, The American review of respiratory disease.

[2]  P. Barnes,et al.  Effect of corticosteroids on airway hyperresponsiveness. , 1990, The American review of respiratory disease.

[3]  P. Barnes,et al.  A new approach to the treatment of asthma. , 1989, The New England journal of medicine.

[4]  N. Thomson.  Nedocromil sodium: an overview. , 1989, Respiratory medicine.

[5]  P. Barnes,et al.  New concepts in the pathogenesis of bronchial hyperresponsiveness and asthma. , 1989, The Journal of allergy and clinical immunology.

[6]  P. Small.  Anti-inflammatory therapy in asthma. , 1989, Annals of allergy.

[7]  S. Holgate.  The Role of Inflammatory Processes in Airway Hyperresponsiveness. , 1989 .

[8]  A. Ahmed,et al.  Corticosteroids: a review with emphasis on complications of prolonged systemic therapy. , 1989, Annals of allergy.

[9]  E. R. Mcfadden,et al.  Corticosteroids and cromolyn sodium as modulators of airway inflammation. , 1988, Chest.

[10]  I. Bernstein,et al.  An open study of auranofin in the treatment of steroid-dependent asthma. , 1988, The Journal of allergy and clinical immunology.

[11]  R. Dahl,et al.  Evaluation of the addition of cromolyn sodium to bronchodilator maintenance therapy in the long-term management of asthma. , 1987, The Journal of allergy and clinical immunology.

[12]  S. Crooke,et al.  The cellular pharmacology of auranofin. , 1987, Seminars in arthritis and rheumatism.

[13]  W. Klaustermeyer,et al.  Chrysotherapy in the treatment of corticosteroid-dependent asthma. , 1987, The Journal of allergy and clinical immunology.

[14]  D. Cockcroft,et al.  Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine. , 1987, The Journal of allergy and clinical immunology.

[15]  Z. Honda,et al.  Differential inhibitory effects of auranofin on leukotriene B4 and leukotriene C4 formation by human polymorphonuclear leukocytes. , 1987, Biochemical pharmacology.

[16]  W. Klaustermeyer,et al.  Corticosteroid complications in respiratory disease. , 1987, Annals of allergy.

[17]  Phillips Yy,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. , 1987, The American review of respiratory disease.

[18]  R. Pietrusko,et al.  Long-term efficacy and safety of auranofin: a review of clinical experience. , 1986, Scandinavian journal of rheumatology. Supplement.

[19]  P. Sterk,et al.  Inhalation Challenge Tests and Airway Responsiveness in Man , 1985 .

[20]  A. Miller,et al.  Standardized lung function testing. , 1984, Bulletin europeen de physiopathologie respiratoire.

[21]  T. Miyamoto,et al.  Auranofin, an oral chrysotherapeutic agent, inhibits histamine release from human basophils. , 1984, The Journal of allergy and clinical immunology.

[22]  D E Griswold,et al.  Biologic actions and pharmacokinetic studies of auranofin. , 1983, The American journal of medicine.

[23]  M. Guttadauria,et al.  Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. , 1983, Arthritis and rheumatism.

[24]  P. Davis,et al.  Effects of gold compounds on the function of phagocytic cells. I. Suppression of phagocytosis and the generation of chemiluminescence by polymorphonuclear leukocytes. , 1982, The Journal of rheumatology. Supplement.

[25]  M. Scheinberg,et al.  The effect of auranofin and sodium aurothiomalate on peripheral blood monocytes. , 1982, The Journal of rheumatology.

[26]  K. Nakajima,et al.  Bronchial responsiveness to acetylcholine in patients with bronchial asthma after long-term treatment with gold salt. , 1981, The Journal of allergy and clinical immunology.

[27]  M. Muranaka,et al.  Gold salt in the treatment of bronchial asthma--a double-blind study. , 1978, Annals of allergy.